Review

. 2024 May:65:101196.

doi: 10.1016/j.blre.2024.101196. Epub 2024 Mar 27.

Chronic myeloid leukaemia: Biology and therapy

Yun Wang¹, Zhi-Jian Liang¹, Robert Peter Gale², Hua-Ze Liao¹, Jun Ma³, Tie-Jun Gong⁴, Ying-Qi Shao⁵, Yang Liang⁶

Affiliations

¹ Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
² Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
³ Harbin Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, China.
⁴ Harbin Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, China. Electronic address: gongtiejun678@163.com.
⁵ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic address: shaoyingqi@ihcams.ac.cn.
⁶ Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic address: liangyang@sysucc.org.cn.

PMID: 38604819
DOI: 10.1016/j.blre.2024.101196

Review

Chronic myeloid leukaemia: Biology and therapy

Yun Wang et al. Blood Rev. 2024 May.

. 2024 May:65:101196.

doi: 10.1016/j.blre.2024.101196. Epub 2024 Mar 27.

Authors

Yun Wang¹, Zhi-Jian Liang¹, Robert Peter Gale², Hua-Ze Liao¹, Jun Ma³, Tie-Jun Gong⁴, Ying-Qi Shao⁵, Yang Liang⁶

Affiliations

¹ Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
² Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
³ Harbin Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, China.
⁴ Harbin Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, China. Electronic address: gongtiejun678@163.com.
⁵ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic address: shaoyingqi@ihcams.ac.cn.
⁶ Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic address: liangyang@sysucc.org.cn.

PMID: 38604819
DOI: 10.1016/j.blre.2024.101196

Abstract

Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.

Keywords: BCR::ABL1; Chronic myeloid leukaemia; Quality-of-life; Treatment-free remission; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing Interest RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd. Fig. 2 and Fig. 3–4 were created with BioRender and Figdraw, respectively.

Cited by

Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review.
Wang Y, Liu Q, Xu CL, Huang DP, Chen Y. Wang Y, et al. Ann Hematol. 2025 May;104(5):3047-3051. doi: 10.1007/s00277-025-06351-9. Epub 2025 Apr 9. Ann Hematol. 2025. PMID: 40202540 Free PMC article. Review.
Hematological malignancy burden in mainland China and Taiwan from 1990 to 2021 and decadal projections: Insights from the global burden of disease study 2021.
Fu Y, Du YZ, Zhang YW, Song F, Gao SJ, Su L. Fu Y, et al. PLoS One. 2025 Jul 21;20(7):e0328526. doi: 10.1371/journal.pone.0328526. eCollection 2025. PLoS One. 2025. PMID: 40690460 Free PMC article.
Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature.
Zhang Y, Li A. Zhang Y, et al. Open Med (Wars). 2025 Apr 23;20(1):20251184. doi: 10.1515/med-2025-1184. eCollection 2025. Open Med (Wars). 2025. PMID: 40292250 Free PMC article.
Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia.
Chavaro-Francisco G, Hernández-Zavala A, Bravo-Cidro CE, Rios-Rodriguez S, Muciño-Sánchez M, López-López M, Castro-Martínez XH, Olarte-Carrillo I, Garcia-Laguna A, Barranco-Lampón G, De la Cruz-Rosas A, Martínez-Tovar A, Córdova EJ. Chavaro-Francisco G, et al. Genes (Basel). 2024 Aug 10;15(8):1054. doi: 10.3390/genes15081054. Genes (Basel). 2024. PMID: 39202414 Free PMC article.
Molecular monitoring in CML-a modern example of an old proverb.
Lipton JH. Lipton JH. Blood Cancer J. 2024 Nov 28;14(1):211. doi: 10.1038/s41408-024-01192-7. Blood Cancer J. 2024. PMID: 39609389 Free PMC article. No abstract available.

See all "Cited by" articles

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chronic myeloid leukaemia: Biology and therapy

Affiliations

Chronic myeloid leukaemia: Biology and therapy

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous